|
|
Article: Evotec Halts Development Of EVT.301 In Alzheimer's.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BioWorld International Correspondent
Evotec AG discontinued development of its candidate for Alzheimer's disease, EVT.301, following indications of potential liver toxicity during a Phase I trial in healthy volunteers.
The Hamburg, Germany-based company had been testing the compound, an inhibitor of the mitochondrial enzyme monoamine oxidase B (MAO-B), in both elderly and young volunteers. Some time after the 28-day dosing period had ended, elevated liver function tests were observed in the elderly but not the young group. The effect was asymptomatic and resolved itself spontaneously.
"It's a finding which is quite surprising and which we ...